Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Netarsudil effect on retinal circulation
NCT04234932Phase 1Unknown
- Sponsor
- University of the Incarnate Word
- Start
- Jan 2020
- Primary completion
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1 trial of netarsudil in Open-angle glaucoma (OAG) (2 arms), sponsored by University of the Incarnate Word. Primary endpoint: Peripapillary capillary perfusion density at 90 minutes. Status: unknown.
02
Drugs
netarsudil
03
Conditions
Open-angle glaucoma (OAG)
Beyond the preview
Go deeper on NCT04234932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04234932.